Kapetanovic et al reported that therapy with rituximab or abatacept may interfere with a patient’s immune reponse to vaccination.
Features:
(1) A patient is being treated with rituximab or abatacept.
(2) The patient is vaccinated.
(3) The antibody response to the vaccine is impaired.
Vaccines studied:
(1) pneumococcal conjugate vaccine
(2) HIN1 influenza
The impact can be increased by other risk factors for impaired antibody response such as advanced age or smoking.
Significance:
(1) A patient should be vaccinated prior to starting therapy with rituximab or abatacept.
(2) The patient may be at risk for vaccine preventable infections if therapy is given long-term.
To read more or access our algorithms and calculators, please log in or register.
Specialty: Infectious Diseases, Pharmacology, clinical
